No impact of age on outcome in chronic myeloid leukemia patients treated with imatinib, study suggests
Wednesday, March 30, 2011 - 13:30
in Health & Medicine
While the median age at diagnosis for chronic myeloid leukemia (CML) is over 60 years old, limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML. New results, however, reveal that age does not affect response to imatinib and overall survival is similar in older and younger patients treated with the drug.